Clinical trial
A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in…
NCT00458146 · Merrimack Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00458146 |
|---|---|
| Title | A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis |
| Official title | A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate |
| Lead sponsor | Merrimack Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | MM-093 |
| Enrollment | 100 |
| Start date | Feb 1, 2007 |
| First posted | Apr 9, 2007 |
| Last update posted | Mar 27, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: